- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01155674
Innate Immune Functions of Immature Neutrophils
July 1, 2010 updated by: University Hospital, Geneva
Polymorphonuclear neutrophils, or granulocytes, are essential effector cells of the innate immune system against bacterial infections.
Their role in sepsis has been long established as the primary phagocyte to clear the infectious process.
In the early phase of sepsis, one observes a massive recruitment of immature neutrophils from the bone marrow into peripheral blood, the so-called "band forms" or "left shift cells".
Despite the daily clinical use of neutrophil band forms count in the care of septic patients and their abundance in septic blood, no information exists on the fate of these cells, nor on their capacity to mount an efficient innate immune response.
It is the goal of this proposal to study the fate and the innate immune functions of immature neutrophils obtained in patients with early septic shock.
Immature neutrophils will be separated from mature neutrophils.
The following functions will be studied ex vivo in mature vs. immature neutrophils from a series of patients with severe sepsis and septic shock: (1) surface expression of receptors of the innate immunity; (2) production of inflammatory mediators and reactive oxygen species in response to bacterial agonists; (3) chemotaxis; (4) phagocytosis of Gram-positive and Gram-negative bacteria; and (5) ex vivo viability (life span) and resistance to apoptosis.
Importantly, the investigators have developed and mastered all in vitro assays and cell separation techniques necessary to address and answer these important questions.
This project will undoubtedly shed light on the fate and function of a prominent leukocyte population circulating in patients with severe bacterial infections and sepsis.
Study Overview
Detailed Description
Objectives
- Primary objective: To determine the innate immune functions of immature neutrophils in comparison to those from mature neutrophils, sampled from patients with severe sepsis and sepsis shock and in control patients (trauma patients and healthy donors (only mature neutrophils in the latter case)
- Secondary objectives: To determine the fate and span life of immature neutrophils in comparison to mature neutrophils, sampled from patients with severe sepsis and sepsis shock and in control patients (trauma patients and healthy donors (only mature neutrophils in the latter case).
Inclusion criteria
- Patients with severe sepsis or septic shock (according to ACCP/FCCM standard definitions) with > 5% immature neutrophils.
- Patients with a noninfectious systemic inflammatory response syndrome (SIRS), e.g. patients with head trauma or multiple trauma with > 5% immature neutrophils.
- Healthy donors
Exclusion criteria
- Severe immunosuppression (e.g. HIV with < 200 CD4/mm3), treatment with glucocorticoids (> 300 mg hydrocortisone/day) or other immunosuppressive therapy
- Neutropenia (neutrophils < 0.5 G/l).
- Recent chemotherapy or administration of intravenous immunoglobulins within the last 4 weeks.
Endpoints
- Surface expression of receptors of the innate immunity in immature vs. mature neutrophils.
- Production by immature vs. mature neutrophils of inflammatory mediators and reactive oxygen species in response to bacterial agonists.
- Chemotaxis of immature vs. mature neutrophils.
- Phagocytosis of Gram-positive and Gram-negative bacteria by immature vs. mature neutrophils.
- Ex vivo viability and resistance to apoptosis of immature vs. mature neutrophils.
Study Type
Observational
Enrollment (Anticipated)
60
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Geneva, Switzerland, 1211
- Recruiting
- University Hospitals of Geneva, Intensive Care
-
Contact:
- Jerome Pugin, MD
- Email: jerome.pugin@unige.ch
-
Sub-Investigator:
- Geneviève Drifte, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
- Patients with severe sepsis or septic shock
- Patients with a noninfectious systemic inflammatory response syndrome (SIRS)
- Healthy donors
Description
Inclusion Criteria:
- Patients with severe sepsis or septic shock (according to ACCP/FCCM standard definitions) with > 5% immature neutrophils.
- Patients with a noninfectious systemic inflammatory response syndrome (SIRS), e.g. patients with head trauma or multiple trauma with > 5% immature neutrophils.
- Healthy donors
Exclusion Criteria:
- Severe immunosuppression (e.g. HIV with < 200 CD4/mm3), treatment with glucocorticoids (> 300 mg hydrocortisone/day) or other immunosuppressive therapy
- Neutropenia (neutrophils < 0.5 G/l).
- Recent chemotherapy or administration of intravenous immunoglobulins within the last 4 weeks.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
|---|
|
Sepsis patients
Patients presenting sepsis
|
|
SIRS patients
Patients presenting with the systemic inflammatory response syndrome
|
|
Healthy subjects
Healthy blood donors
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Innate immune functions of neutrophils
Time Frame: 12 months
|
|
12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2010
Primary Completion (Anticipated)
August 1, 2011
Study Completion (Anticipated)
October 1, 2011
Study Registration Dates
First Submitted
July 1, 2010
First Submitted That Met QC Criteria
July 1, 2010
First Posted (Estimate)
July 2, 2010
Study Record Updates
Last Update Posted (Estimate)
July 2, 2010
Last Update Submitted That Met QC Criteria
July 1, 2010
Last Verified
February 1, 2010
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- CER 09-311
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sepsis
-
University of California, San FranciscoNational Cancer Institute (NCI)RecruitingSepsis | Sepsis, Severe | Sepsis and Septic Shock | Sepsis at Intensive Care Unit | Sepsis, Septic Shock | Sepsis, Severe Sepsis and Septic Shock | Sepsis With Multiple Organ Dysfunction (MOD) | Sepsis With Acute Organ DysfunctionUnited States
-
Assiut UniversityNot yet recruitingSepsis Induced Myocardial Dysfunction | Sepsis Induced CardiomyopathyEgypt
-
University of Kansas Medical CenterUniversity of KansasRecruitingSepsis | Septic Shock | Sepsis Syndrome | Sepsis, Severe | Sepsis Bacterial | Sepsis BacteremiaUnited States
-
Jip GroenInBiomeRecruitingMicrobial Colonization | Neonatal Infection | Neonatal Sepsis, Early-Onset | Microbial Disease | Clinical Sepsis | Culture Negative Neonatal Sepsis | Neonatal Sepsis, Late-Onset | Culture Positive Neonatal SepsisNetherlands
-
The University of QueenslandRoyal Brisbane and Women's HospitalUnknown
-
Karolinska InstitutetÖrebro University, SwedenCompletedSepsis | Sepsis Syndrome | Sepsis, SevereSweden
-
Ohio State UniversityCompletedSepsis, Severe Sepsis and Septic ShockUnited States
-
Indonesia UniversityCompletedSevere Sepsis With Septic Shock | Severe Sepsis Without Septic ShockIndonesia
-
University of LeicesterUniversity Hospitals, Leicester; The Royal College of AnaesthetistsCompletedSepsis | Septic Shock | Severe Sepsis | Sepsis SyndromeUnited Kingdom
-
Beckman Coulter, Inc.Biomedical Advanced Research and Development AuthorityEnrolling by invitationSevere Sepsis | Severe Sepsis Without Septic ShockUnited States